sildenafil citrate (oral therapy)
Last edited 02/2020
This is an oral therapy that has a UK license for erectile dysfunction.
It is a phosphodiesterase 5 (PDE5) inhibitor which in turn enhances the effect of nitric oxide. Nitric oxide acts on enzymes which enable smooth-muscle relaxation in the corpus cavernosum, allowing an inflow of blood, and resulting in a penile erection.
Sildenafil citrate is contra-indicated in patients taking organic nitrates (1).
Reported side effects include flushing, headache, dyspepsia, nasal congestion, dizziness, diarrhoea, rashes and UTIs. There have been six reports of deaths (related to MIs) occurring in users of sildenafil citrate. It is unclear whether sildenafil citrate reacted with prescribed heart medication or the deaths were the result of unaccustomed sexual exertion.
Ref:Bandolier (1998), 5(7),1-4.
interactions and contraindications
comparisons with other therapies
phosphodiesterase (PDE5) inhibitors in erectile dysfunction
comparison of onset and duration of action of different phosphodiesterase (PDE5) inhibitors
eligible groups for NHS funding for erectile dysfunction (ED)